Organigram Global (OGI) said Wednesday it has expanded its investment in Phylos Bioscience through an amended loan and product agreement.
Under the amended agreement, Organigram said it will consolidate its existing investment with a new $3 million advance, bringing the loan principal amount to $10 million. The loan matures on May 25, 2028.
Organigram said that under the agreement, it will receive five-year exclusivity on its chosen autoflower cultivars across Canada, Australia, the UK, Germany, and Israel, with the option to expand further into new markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments